Acute exacerbation impairs endothelial function in patients with chronic obstructive pulmonary disease

Turk Kardiyoloji Dernegi Arsivi

Volumn 38, Issue 1, 2010, Pages 1-7

  Özben, Beste ^a   Eryüksel, Emel ^a   Tanrikulu, Azra Meryem ^a   Papila Topal, Nurdan ^a   Çelikel, Turgay ^a   Başaran, Yelda ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

Brachial artery ultrasonography; Chronic obstructive; Endothelium; Pulmonary disease; Vascular

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; BRACHIAL ARTERY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPEREMIA; LUNG FUNCTION TEST; MALE;

AGED; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERENCE VALUES; VASODILATION; VITAL CAPACITY;

EID: 77952302947     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002;57:1067-1070
2. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005;99:670-682
3. Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:5s-13s. (Pubitemid 37351732)
4. Agustí AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-360 (Pubitemid 36204553)
5. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-874 (Pubitemid 44564786)
6. Sapey E, Stockley RA. COPD exacerbations · 2: aetiology. Thorax 2006;61:250-258
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809
8. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115
9. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003;108:2054-2059 (Pubitemid 37337577)
10. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993;92:652-662 (Pubitemid 23262382)
11. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88(5 Pt 1):2149-2155 (Pubitemid 23326094)
12. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest 1994;93:50-55 (Pubitemid 24030819)
13. de Groot PG, Willems C, Boers GH, Gonsalves MD, van Aken WG, van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983;13:405-410
14. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-265 (Pubitemid 34084631)
15. Deng YB, Wang XF, Le GR, Zhang QP, Li CL, Zhang YG. Evaluation of endothelial function in hypertensive elderly patients by high-resolution ultrasonography. Clin Cardiol 1999;22:705-710 (Pubitemid 29510999)
16. Leeson P, Thome S, Donald A, Mullen M, Clarkson P, Deanfield J. Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 1997;78:22-27 (Pubitemid 27346876)
17. Karoli NA, Rebrov AP, Iudakova IuN. Vascular endothelial dysfunction in patients with chronic obstructive lung diseases. Probl Tuberk Bolezn Legk 2004;(4):19-23. [Abstract]
18. Peinado VI, Barbera JA, Ramirez J, Gomez FP, Roca J, Jover L, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998;274(6 Pt 1):L908-13.
19. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001;46:798-825.
20. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. (Pubitemid 17009877)
21. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-664
22. Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993;103:536-540 (Pubitemid 23070759)
23. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-715
24. Engström G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106:2555-2560 (Pubitemid 35340691)
25. Friedman GD, Klatsky AL, Siegelaub AB. Lung function and risk of myocardial infarction and sudden cardiac death. N Engl J Med 1976;294:1071-1075
26. Schroeder EB, Welch VL, Evans GW, Heiss G. Impaired lung function and subclinical atherosclerosis. The ARIC Study. Atherosclerosis 2005;180:367-373
27. Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology 2008;59:357-364
28. Karoli NA, Rebrov AP. Vasoregulating activity of the endothelium and pulmonary hypertension. Ter Arkh 2004;76:39-44. [Abstract]
29. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000;321:199-204. (Pubitemid 30459555)
30. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 1999;130:933-937
31. Mendes ES, Horvath G, Rebolledo P, Monzon ME, Casalino-Matsuda SM, Wanner A. Effect of an inhaled glucocorticoid on endothelial function in healthy smokers. J Appl Physiol 2008;105:54-57
32. Harris RA, Nishiyama SK, Wray DW, Berkstressor KA, Richardson RS. Oxidative stress and exercise-induced flow-mediated dilation in COPD: Insight into skeletal muscle dysfunction. FASEB J 2008;22:1235-1315 [Abstract]
33. Karoli NA, Rebrov AP. The study of circulating endothelial cells in patients with bronchial asthma. Klin Med 2003;81:22-25 [Abstract]
34. Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 1999;160:1968-1975.
35. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-215 (Pubitemid 30601465)
36. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001;56:30-35 (Pubitemid 32041716)
37. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997;10:846-850 (Pubitemid 27180197)
38. Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:572-579 (Pubitemid 40468504)
39. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000;55:114-120 (Pubitemid 30245950)
40. Hill AT, Bayley DL, Campbell EJ, Hill SL, Stockley RA. Airways inflammation in chronic bronchitis: the effects of smoking and alphal-antitrypsin deficiency. Eur Respir J 2000;15:886-890
41. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154(4 Pt 1):1055-1060 (Pubitemid 126679546)
42. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-1203
43. Praticò D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 1998;158:1709-1714 (Pubitemid 29008804)
44. Skyba P, Joppa P, Orolín M, Tkácová R. Blood pressure and heart rate variability response to noninvasive ventilation in patients with exacerbations of chronic obstructive pulmonary disease. Physiol Res 2007;56:527-533